Natco Pharma gets USFDA EIR on pharmacovigilance requirements

Telangana: Natco Pharma has informed in a BSE filing that the Company has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA).

In November, Natco Pharma informed of the successful completion of the USFDA inspection of the firm’s compliance with Pharmacovigilance requirements with zero observations.

"We bring to your notice that the Company is in receipt of the Establishment Inspection Report (EIR) from USFDA concluding the inspection as Closed," Natco Pharma stated.

Read also: Natco Pharma Pharmacovigilance department successfully completes USFDA inspection

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 employees, Natco today has eight manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.

Read also: Natco Pharma reports over 3-fold rise in net profit at Rs 212.7 crore in Q3